Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL591061 | 0.83 | NOS1 (0.38) | ADORA2AADORA1 | |
| SCHEMBL591584 | 0.78 | NOS1 (0.34) | — | |
| SCHEMBL590762 | 0.76 | MAPT (0.35) | — | |
| SCHEMBL23428444 | 0.73 | ALDH1A1 (0.44) | — | |
| SCHEMBL11644414 | 0.72 | ALDH1A1 (0.41) | — | |
| SCHEMBL592097 | 0.71 | SIGMAR1 (0.42) | — | |
| SCHEMBL589220 | 0.69 | RORC (0.31) | — | |
| SCHEMBL592332 | 0.69 | HTR7 (0.40) | — | |
| SCHEMBL24368067 | 0.69 | CA12 (0.44) | — | |
| SCHEMBL589800 | 0.67 | S100B (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120932-B1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES SRL (IT) | 2014-07-09 | — | — | EP | disclosed |
| US-8114865-B2 | Indazole derivatives as kinase inhibitors for the treatment of cancer | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-14 | — | — | US | disclosed |
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-08-05 | — | — | US | disclosed |
| CN-101594862-A | Substituted indazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2009-12-02 | — | — | CN | disclosed |
| EP-2120932-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Nerviano Medical Sciences S.r.l. (IT) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008074749-A9 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES SRL (IT) | 2009-05-07 | — | — | WO | disclosed |
| WO-2008074749-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | MAP3K5, MAP3K19, MAP3K3 | ADORA2A 3342/4885ADORA1 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.